Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Chaza Alaji: DVT in Early Pregnancy – Why Anticoagulation Decisions Matter
Nov 21, 2026, 12:13

Chaza Alaji: DVT in Early Pregnancy – Why Anticoagulation Decisions Matter

Chaza Alaji, Medical Laboratory Specialist and Supervisor at Privat University-Private Laboratory-General Hospital, shared a post on LinkedIn:

“Deep Vein Thrombosis in Early Pregnancy: Why Anticoagulation Decisions Matter

Deep vein thrombosis (DVT) during the first trimester is a potentially serious condition requiring prompt diagnosis and

treatment to protect maternal health and reduce the risk of pulmonary embolism (PE).

Why does pregnancy increase thrombosis risk?

Pregnancy promotes hypercoagulability through Virchow’s triad:

Hypercoagulability: Increased fibrinogen and clotting factors VII, VIII and X, reduced Protein S activity, and decreased fibrinolysis.

Venous stasis: Hormonal changes reduce venous return; later, the enlarging uterus may compress pelvic veins.

Vascular changes: Pregnancy-related changes may contribute to coagulation activation.

VTE risk is highest during the postpartum period, particularly the first six weeks.

Major risk factors

  • Previous VTE or inherited thrombophilia, including Factor V Leiden, Prothrombin G20210A, and deficiencies of Antithrombin, Protein C or Protein S.
  • Antiphospholipid syndrome (APS).
  • Obesity, maternal age over 35, and cancer.
  • Immobility, hospitalization, and systemic infection.
  • Assisted reproductive technology (IVF/ART).
  • Ovarian hyperstimulation syndrome (OHSS), severe hyperemesis, and dehydration.
  • Conditions such as SLE and nephrotic syndrome.

Treatment: Why is LMWH preferred?

According to the 2025 ESC pregnancy guidelines, low-molecular-weight heparin (LMWH), such as enoxaparin, is the preferred treatment for acute VTE during pregnancy.

Key advantages:

Does not cross the placenta.

Has predictable pharmacokinetics.

Carries lower risks of heparin-induced thrombocytopenia (HIT) and osteoporosis than unfractionated heparin (UFH).

Therapeutic dosing is based on the mother’s early-pregnancy body weight and may be given once or twice daily. Routine anti-Xa monitoring is not required for most patients, but may be considered in selected cases, such as renal impairment or extreme obesity.

Which anticoagulants should be avoided?

  • Warfarin: Crosses the placenta and may cause fetal embryopathy, bleeding, and other complications.
  • Direct oral anticoagulants (DOACs): Not recommended because placental transfer is possible and fetal safety data remain insufficient.

Diagnosis and duration of treatment

Compression duplex ultrasound is the first-line investigation. If the initial scan is negative but clinical suspicion remains high, repeat imaging or further assessment may be necessary.

Treatment should continue throughout pregnancy and for at least 6 weeks postpartum, with a minimum total treatment duration of 3 months.

Clinical take-home message

  • DVT in early pregnancy requires prompt recognition, individualized risk assessment, and appropriate anticoagulation.
  • LMWH remains the preferred treatment, with coordinated care involving obstetric and hematology teams.
  • Early diagnosis and appropriate anticoagulation are essential for maternal and fetal safety.”

Chaza Alaji: DVT in Early Pregnancy - Why Anticoagulation Decisions Matter

Other posts featuring Chaza Alaji on Hemostatis Today.